<DOC>
	<DOCNO>NCT00658008</DOCNO>
	<brief_summary>This 10-week trial evaluate efficacy safety PD 0332334 subject , age 18 65 , generalize anxiety disorder .</brief_summary>
	<brief_title>A 10-week Study Evaluating Efficacy Safety PD 0332334 Patients With Generalized Anxiety Disorder ( 1 )</brief_title>
	<detailed_description>Termination reason : On February 23rd 2009 , decision terminate development PD 0332334 communicate investigator study . The decision terminate study base safety concern .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Diagnosis GAD ( Diagnostic Statistical Manual IV [ DSM IV ] , 300.02 ) establish clinician ( psychiatrist license clinical psychologist ) interview subject use source data include Mini International Neuropsychiatric Interview ( MINI ) DSM IV Axis I disorder clinical information . Subjects specific phobia ( ) ( define DSM IV ) dysthymic disorder allow study . Subjects must HAM A total score ≥20 screening ( V1 ) randomization ( V2 ) visit . Subjects must also Covi Anxiety Scale score ≥9 Raskin Depression Scale score ≤7 Screening ( V1 ) visit ensure predominance anxiety symptom depression symptom . Subjects evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , pancreatic , neurologic , active infection , immunological , allergic disease ( include drug allergy ) . Any follow current ( within past 6 month present ) DSMIV Axis I diagnosis : Major Depressive Disorder , Obsessive Compulsive Disorder , Panic Disorder , Agoraphobia , Posttraumatic Stress Disorder , Anorexia , Bulimia , Caffeine induce anxiety disorder , Alcohol substance abuse dependence unless full remission least 6 month , Social Anxiety Disorder . Any follow past current DSMIV Axis I diagnose : Schizophrenia , Psychotic disorder , Delirium , dementia , amnestic , clinically significant cognitive disorder , Bipolar schizoaffective disorder , Cyclothymic disorder , Dissociative disorder . Antisocial borderline personality disorder . Serious suicidal risk per clinical investigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>PD 0332334 phase 3 pivotal trial</keyword>
</DOC>